ESC 2018 Dr. Ajay Gupta investigated the long term effects of treatment with a calcium channel blocker-based regimen and a statin on mortality in patients with hypertension, and showed a legacy effect of the combined therapy.

ESC 2018 Across the world, one out of five people has hypertension. In this video dr. Thomas Beaney shares the first results of the May Measurement Month project, which aims to raise awareness of high blood pressure globally in prevention of CVD.

ESC 2018 Dr. Dorresteijn presents how the lifetime risk model U-prevent can estimate the effect of preventive treatment and explains the value of this model in shared decision-making.

ESC 2018 Biomarkers play an important role in CV risk prediction. Nina Paynter, PhD, presents the definition of a good biomarker and explains how deep learning can improve CV risk assessment.

ESC 2018 Women are still underrepresented in CV clinical trials. Dr. Jeanine Roeters van Lennep explains why sex-specific analyses are important in research into efficacy and safety of CV medication.

ESC 2018 Nicole Jaspers, MD, presents a model that predicts lifetime risk of CV events in individuals without CVD, including lifetime benefit of therapy, which allows shared-decision making in daily practice.

ESC 2018 Prof. dr. Pieter Vandervoort, Jean-Paul Vendeville and Gijs Berkelmans discuss how digital health can help us screening for atrial fibrillation in general population by using a smartphone.

ESC 2018 Cilie van 't Klooster asks Prof. Ridker how the results on canakinumab from the CANTOS trial can be implemented in clinical practice and which challenges are left?

ESC 2018 The benefit of sacubitril/valsartan in HFrEF is not subject to debate, but opinions do vary on when to use it. An impression of the arguments on whether or not it should be the starting treatment.

ESC 2018 In a randomized trial treatment with tafamidis resulted in impressive, significant reduced mortality and hospitality due to CV events in patients with ATTR-CM and HF.

ESC 2018 Dr Allard-Ratick shares the surprising result that HDL-C levels >60 mg/dl (1.5 mmol/L) were associated with a nearly two-fold increase in the risk of CV death or MI in adults with CV disease.

ESC 2018 In one of this year’s organized debates, it was discussed how the COMPASS trial results should or should not change clinical practice; an impression of the arguments of both sides.